ArticleFoot & ankle international2026
Arthroscopic Bone Marrow Stimulation for Non-primary Osteochondral Lesions of the Talus Yields Limited Improvements in Patient-Reported Outcomes Compared to Primary Lesions: A Prospective 2-Year Follow-up Study.
Article in Foot & ankle international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur aim in this study was to prospectively assess the patient-reported clinical outcomes of arthroscopic bone marrow stimulation (BMS) for non-primary osteochondral lesions of the talus (OLT) and to compare these with primary cases at 2-year follow-up. The secondary aims were to assess the association of baseline factors with outcomes and the occurrence of adverse events.
methodsPatients who underwent arthroscopic BMS were prospectively included and assessed up to 2-year follow-up and were grouped according to non-primary (ie, failed previous OLT surgery) or primary BMS. Patient-reported outcomes were collected at baseline and 2-year follow-up and included the numeric rating scale (NRS) for pain and the Foot and Ankle Outcome Score (FAOS) questionnaires. The primary outcome was the improvement in NRS pain during walking, with a minimal clinically important difference (MCID) of 2.0. Adverse events concerned reoperations and complications during the study period.
resultsForty-four patients were included: 25 in the primary group and 19 in the non-primary group. Both groups showed a statistically significant improvement in pain and functional outcomes from preoperatively to 2-year follow-up. The improvement in the primary outcome was significantly higher in the primary group (median 3 [IQR: 1-5] out of 10) compared to the non-primary group (median 1 [IQR: 1-3] out of 10),
conclusionThe most important finding of this prospective study is that arthroscopic BMS for non-primary OLT yields a significant improvement in patient-reported outcomes compared with baseline, but an inferior improvement compared with primary OLT at 2-year follow-up. On average, approximately two-thirds of BMS-treated primary OLTs reached the MCID compared with one-third in the non-primary group. LEVEL OF EVIDENCE: Level II, prospective comparative cohort study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.